WallStSmart

Johnson & Johnson (JNJ)vsSotera Health Co (SHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 7952% more annual revenue ($97.93B vs $1.22B). JNJ leads profitability with a 21.5% profit margin vs 13.4%. SHC appears more attractively valued with a PEG of 1.68. SHC earns a higher WallStSmart Score of 66/100 (B-).

JNJ

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 8.5Value: 3.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64

SHC

Strong Buy

66

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 4.3Quality: 4.5
Piotroski: 4/9Altman Z: 0.71

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$640.02B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
21.5%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
29.2%8/10

Strong operational efficiency at 29.2%

Free Cash FlowQuality
$3.39B8/10

Generating 3.4B in free cash flow

SHC2 strengths · Avg: 10.0/10
Operating MarginProfitability
38.0%10/10

Strong operational efficiency at 38.0%

EPS GrowthGrowth
570.0%10/10

Earnings expanding 570.0% YoY

Areas to Watch

JNJ4 concerns · Avg: 2.8/10
P/E RatioValuation
30.9x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.792/10

Expensive relative to growth rate

EPS GrowthGrowth
-0.9%2/10

Earnings declined 0.9%

SHC4 concerns · Avg: 3.5/10
PEG RatioValuation
1.684/10

Expensive relative to growth rate

P/E RatioValuation
32.8x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.0x4/10

Trading at 8.0x book value

Altman Z-ScoreHealth
0.712/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.

Bull Case : SHC

The strongest argument for SHC centers on Operating Margin, EPS Growth.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.

Bear Case : SHC

The primary concerns for SHC are PEG Ratio, P/E Ratio, Price/Book. Debt-to-equity of 3.41 is elevated, increasing financial risk.

Key Dynamics to Monitor

JNJ profiles as a mature stock while SHC is a value play — different risk/reward profiles.

SHC carries more volatility with a beta of 1.78 — expect wider price swings.

SHC is growing revenue faster at 9.2% — sustainability is the question.

JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

SHC scores higher overall (66/100 vs 59/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Sotera Health Co

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.

Want to dig deeper into these stocks?